Join us for a two-day live course that features expert presentations and interactive discussions on the latest advancements and trends in addiction. The course has 10 topics, each with a comprehensive 45-minute presentation followed by a 15-minute Q&A session. The live course will cover diverse topics relevant to addiction psychiatry and is particularly useful for those preparing for ABPN certification and recertification examinations.
Participants will have access to an additional 15 on-demand sessions to further enrich the learning experience.
Don’t miss this opportunity to deepen your knowledge, engage with leading experts, and advance your expertise in addiction.
Registration coming soon.
The field of Addiction changes frequently as new information becomes available. This course presents a broad-based overview of addictions and up-to-date information in the field of addiction. It is recommended for physicians, PA-Cs, nurse practitioners, and other professionals who wish to stay updated on the most recent trends in the addiction field. It is equally relevant to junior faculty and clinicians as well as experienced practitioners and is intended to help psychiatrists prepare for ABPN certification and recertification examinations in Addiction Psychiatry.
At the conclusion of this activity, participants should be able to:
- Describe new advances in pharmacotherapy and psychotherapy of substance use disorders.
- Discuss the epidemiology of substance use disorders and their co-occurrence with other psychiatric disorders and review current recommended approaches for concurrent treatment of substance use disorders and other mental health disorders.
- Describe the role of genetics in the risk for developing alcohol and other substance use disorders.
- Identify the major neurobiological pathways involved in substance disorders.
- Identify the molecular mechanisms that are altered following substance use.
- Review the literature on screening and brief intervention effectiveness and teach this technique so it is applied.
- Review current treatment guidelines and how to utilize them in clinical practice.
- Describe special considerations for substance use diagnosis and treatment for women, underrepresented racial and ethnic minorities, youth, older adults, hospitalized patients, and patients with comorbid health conditions.
- Alcohol
- Cannabis
- Benzodiazepines: The Hidden Epidemic
- General Concepts and Epidemiology
- Neurobiology and Genetics
- Review of Opioids and Treatment of Opioid Use Disorders
- Psychosocial Treatments of the Addictions
- Stimulant-Related Disorders
- Tobacco and Nicotine
- Urine drug testing
On-Demand Topics
- Co-Morbidity of Substance and Other Psychiatric Disorders
- Medical Comorbidities in Patients with Substance Use Disorders
- Emerging Drugs
- Inequities in Addiction Treatment for Racial and Ethnic Minority Populations
- Sex and Drugs: Gender Differences in Substance Use Disorders
- Pain and Addiction
- Behavioral Addictions
- Pregnancy and Substance Use Disorders
- Naloxone Overdose Training
- Motivational Interviewing
- Substance Use Disorder in Hospital Settings
- Forensic Issues in Addiction
- Substance Use Disorders in the Older Adult
- Youth with Substance Use Disorders and Attention Deficit Hyperactivity Disorder
- Suicide and Substance Use Disorders
On-Demand Faculty
- Edward V. Nunes, MD
- Steven L. Batki, MD
- Petros Levounis, MD, MA
- Adina Bowe, MD
- Kathleen T. Brady, MD, PhD
- Roger Chou, MD, FACP
- Timothy W. Fong MD
- Michelle Lofwall. MD
- Carla Marienfeld, MD, DFAPA, FASAM
- Sanchit Maruti, MD, MS
- Laurence M. Westreich, MD
- Louis Trevisan, MD
- Amy Yule, MD
Accreditation Statement
In support of improving patient care, American Academy of Addiction Psychiatry is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE) and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Target Audience Statement
The field of Addiction changes frequently as new information becomes available. This course presents a broad-based overview of addictions and up-to-date information in the field of addiction. It is recommended for physicians, PA-Cs, nurse practitioners, and other professionals who wish to stay updated on the most recent trends in the addiction field. It is equally relevant to junior faculty and clinicians as well as experienced practitioners and is intended to help psychiatrists prepare for ABPN certification and recertification examinations in Addiction Psychiatry.
The activity was designated for learners in the following ways:
Physician Designation Statement
American Academy of Addiction Psychiatry designates this Other activity (23.5 hours of enduring material and 10 hours of live online) for a maximum of 33.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ABPN Diplomates
The American Board of Psychiatry and Neurology has reviewed AAAP's 2024 Addictions and Their Treatment and has approved this program as part of a comprehensive self-assessment program, which is mandated by the ABMS as a necessary component of maintenance of certification. This activity awards 10 Self-Assessment Category 1 CME Credits. The approval period is through June 6, 2026.
AAPA Credit Designation Statement
PAs may claim a maximum of 33.5 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society.
Nurse Practitioners and Registered Nurses
For the purpose of recertification, the American Nurses Credentialing Center accepts AMA PRA Category 1 Credit™ issued by organizations accredited by the ACCME.
Health Professionals Designation Statement
Participants will receive a Certificate of Attendance stating this program is designated for 33.5 AMA PRA Category 1 Credits™. This credit is accepted by the AANP.
Credits subject to change
Presenters
Petros Levounis, MD, MA, serves as professor and chair of the Department of Psychiatry and associate dean at Rutgers New Jersey Medical School. He is also the chief of service at University Hospital in Newark, New Jersey, director of the Northern New Jersey Medication Assisted Treatment Center of Excellence, and president-elect of the American Psychiatric Association. Dr. Levounis came to Rutgers from Columbia University where he served as director of the Addiction Institute of New York from 2002 to 2013.
Dr. Levounis is a Phi Beta Kappa graduate of Stanford University where he studied chemistry and biophysics before receiving his medical education at Stanford University School of Medicine and the Medical College of Pennsylvania. During medical school, he researched the effects of social class on patient-physician relationships in Oxford, England, and received an MA degree in sociology from Stanford. In 1994, he moved to New York City to train in psychiatry at the New York State Psychiatric Institute of Columbia University. He graduated from Columbia earning the National Institute of Mental Health Outstanding Resident Award and went on to complete his fellowship in addiction psychiatry at New York University.
Dr. Levounis has written numerous articles, monographs, and book chapters; has lectured extensively on addiction topics throughout the United States and abroad; and has been interviewed by CBS, ABC, NBC, CNN, FOX, The Martha Stewart Radio Show, The New York Times, and The Washington Post, among others.
Dr. Levounis has served on the boards of the American Society of Addiction Medicine (ASAM) and the American Board of Addiction Medicine, and from 2005 to 2009 chaired the national Committee on Addiction Treatment of the American Psychiatric Association (APA). Dr. Levounis is a Betty Ford Scholar, a recipient of the Association of Gay and Lesbian Psychiatrists’ Distinguished Service Award and the ASAM Educator of the Year Award, and a distinguished fellow of the APA and ASAM. In 2017, he was elected as an honorary member of the World Psychiatric Association.
Dr. Levounis has published fourteen books including the self-help paperback “Sober Siblings: How to Help Your Alcoholic Brother or Sister—and Not Lose Yourself,” the textbook of “Substance Dependence and Co-Occurring Psychiatric Disorders,” “Motivational Interviewing for Clinical Practice,” “The Behavioral Addictions,” “Becoming Mindful,” “LGBTQ Mental Health: The Spectrum of Gender and Sexuality,” “Office-Based Buprenorphine Treatment of Opioid Use Disorder,” now in its second edition, and “Technological Addictions.” Dr. Levounis is currently working on the first textbook of Nature Therapy, which is going to be available in 2023. His books have been translated into French, German, Hungarian, Japanese, Korean, Portuguese, and Spanish.
Dr. Levounis is married to actor Lukas Hassel and lives in New York City.
Dr. David Marcovitz is a board-certified general and addiction psychiatrist at Vanderbilt University Medical Center and the Director of the Division of Addiction Psychiatry in the Department of Psychiatry and Behavioral Sciences. He helped launch the Vanderbilt University Hospital Addiction Consult Service and transitional outpatient Bridge Clinic at VUMC. He also serves as the Principal Investigator for the state-funded Middle TN Opioid Addiction Treatment Hub at Vanderbilt. While completing his addiction psychiatry fellowship at Partners Healthcare / Harvard Medical School, he also worked as a staff psychiatrist receiving additional mentored training in collaborative care in the IMPACT Model at Partners Healthcare in Boston, MA. He is an experienced educator, delivering formal and informal didactics on various addiction-related topics to medical students, residents, fellows and colleagues. He has served as the senior trainer for Tennessee supporting the federally-funded Opioid Response Network to help build addiction treatment capacity across TN. Dr. Marcovitz’ teaching at the regional and national level has focused on models of collaborative care with internal medicine and other specialties and disciplines in addiction treatment in both the inpatient and outpatient setting. He has also presented at national meetings on novel teaching methods and outcome measures in addiction psychiatry. He has published on addiction education methods as well as research at the intersection of treatment of opioid addiction and community mutual help. Dr. Marcovitz serves on the board of directors for the American Academy of Addiction Psychiatry (AAAP).
More information can be found here: https://www.vumc.org/psychiatry/person/david-marcovitz-md
Dr. Nunes is Professor of Psychiatry at Columbia University Medical Center and New York State Psychiatric Institute (NYSPI), Multiple PI of the Greater New York Node of the NIDA Clinical Trials Network (CTN), and Co-Director of the CHOSEN Center at Columbia University. He is a practicing psychiatrist Board Certified in Addiction Psychiatry and Addiction Medicine. He has devoted his career to research on the treatment of opioid, cocaine and other substance use disorders and is nationally and internationally recognized for his work on the evaluation and treatment of co-occurring depression and other psychiatric disorders among patients with substance use disorders and the development of pharmacological and behavioral treatments for substance use disorders, as well as for his work in the CTN testing the effectiveness of behavioral and pharmacological treatments in community-based treatment settings. Dr. Nunes has extensive experience with the design, conduct and analysis of clinical trials of treatments for opioid use disorder, including technology-based interventions and extended-release injections and implants of buprenorphine and naltrexone.
Dr. Renner is Professor of Psychiatry, Boston University School of Medicine, and Associate Chief of Psychiatry for the VA Boston Healthcare System. He graduated from Yale University and Case University School of Medicine and completed his psychiatric residency at the Tufts- New England Medical Center. In 1969, Dr. Renner served as a psychiatrist with the US Navy in Vietnam, and since 1979 he has been working at the Boston VA in their outpatient addiction treatment program. In addition to his clinical activities at the VA, he is Associate Director of the Boston University Medical Center General Psychiatry Residency Program and Director of their Addiction Psychiatry Residency.
Dr. Renner has written and lectured extensively on the treatment of alcoholism and drug addiction. He is a member and former chair of the American Psychiatric Association Council on Addiction Psychiatry, former chair of the APA Council on Adult Psychiatry and former Chair of the APA Expert Advisory Panel on Addiction Psychiatry. In 2018, Dr. Renner co-edited the 2nd edition of the APA Handbook of Office-Based Buprenorphine Treatment for Opioid Use Disorder. He is Past-President of the Board of Directors of the American Academy of Addiction Psychiatry, and a member of the Data Safety Monitoring Board for the Clinical Trials Network of the National Institute on Drug Abuse, a member of the Clinical Advisory Committee of the Physician Health Service of the Massachusetts Medical Society, a Consultant to the Department of Psychiatry, Massachusetts General Hospital, and a member of the faculty of the Harvard Medical School Division on Addictions.
Richard K. Ries, MD, is Professor of Psychiatry, and Director of the Addictions Division in the Department of Psychiatry and Behavioral Sciences at the University of Washington School of Medicine in Seattle, Washington, and Director of the Addiction Treatment services at Harborview Medical Center in downtown Seattle. Dr. Ries received his undergraduate degree from Stanford, medical degree from Northwestern Medical School and completed his psychiatric residency at the University of Washington, Seattle, where he was Chief Resident.
Dr. Ries is board-certified in Psychiatry by the American Board of Psychiatry and Neurology with Added Qualifications in Addiction Psychiatry, and the American Board of Addiction Medicine. A Distinguished Fellow of the American Psychiatric Association and a Fellow of the American Society of Addiction Medicine, he is on the editorial board and a reviewer for several scientific journals and has been involved with numerous research grants from the National Institute of Health. In addition he has been active in both studying and treating persons with opioid use disorders, with involvement in SAMHSA grants and the Harborview Addictions program opioid treatment tracks. He has been senior editor of the key reference text: Principles of Addiction Medicine (editions IV and V, published by the American Society of Addiction Medicine, and a noted expert in the field of Addictions, Suicide and other Co-occurring Disorders. Dr Ries works clinically with patients with complex mental, medical and addiction disorders at Harborview Medical Center in downtown Seattle. He has often been listed as one of the Best Doctors in Seattle by Seattle Magazine, including 2018, 2019, and 2020.
Dr. Sevarino earned his MD, CM at McGill Faculty of Medicine and PhD in molecular biology at the University of Connecticut Health Center. After an internship in Internal medicine, he trained in psychiatry in the dual clinical/basic research tract at the Yale University School of Medicine. For six years thereafter, he was PI on NIH grants examining neurobiological mechanisms underlying cocaine dependence, and since then has transitioned to being a clinician-educator who remained active in clinical research as a member of the MIRECC VA Team in studies examining new treatments for substance use disorders. He was Medical Director of the Newington Mental Health Care Firm, Connecticut VA Healthcare System from Dec. 2004 through Aug. 2017. He was consulting psychiatrist to Gaylord Hospital, Wallingford from 1999 – 2009, and again 2017-2023. He now works as per diem psychiatrist at Hartford Healthcare – Rushford. His particular expertise is in treatment of the dually-diagnosed and non-opiate pharmacological management of chronic pain. He is Associate Clinical Professor of Psychiatry, Yale University School of Medicine. He was subspecialty certified in Psychosomatic Medicine by the American Board of Psychiatry and Neurology from 2009 - 2019, in Addiction Medicine by the American Board of Addiction Medicine from 2010 - 2020, and currently in Addiction Medicine by the American Board of Preventative Medicine. Dr. Sevarino serves as Medical Director for the American Academy of Addiction Psychiatry (AAAP), and is a past president of that organization. He was Course Director for the AAAP Board Review Course in Addictions, which developed into the Addictions and Their Treatment Course, from 2007 - 2015. He currently co-directs AAAP’s Advanced Addiction Psychopharmacology course.
Jill M. Williams, MD, is Professor of Psychiatry and Director of the Division of Addiction Psychiatry at the Rutgers University-Robert Wood Johnson Medical School in New Brunswick. She also holds faculty appointments at the Cancer Institute of New Jersey and the Rutgers Center for Alcohol Studies. The focus of Dr. Williams work has been in addressing tobacco in individuals with mental illness or other addictions through treatment and systems interventions. She is Medical Director for the TCTTAC Program in NYC, in collaboration with Center for Practice Innovation at Columbia University. In 2015 she was the recipient of the Remarkable Achievement Award of the NJ Psychiatric Association. She is past Chair and current member of the APA Council on Addiction Psychiatry.
Note: You can find previously recorded courses on the Educational Opportunities page.